Synapse - Ariela Noy

Results (373)

The PARP inhibitor veliparib can be safely added to bendamustine and rituximab and has preliminary evidence of activity in B-cell lymphoma

Journal Article

Soumerai, J. D.; Zelenetz, A. D.; Moskowitz, C. H.; Palomba, M. L.; Hamlin, P. A. Jr; Noy, A.; Straus, D. J.; Moskowitz, A. J.; Younes, A.; Matasar, M. J.; more...
Clinical Cancer Research (2017)

Fulltext@MSK | Save

Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma

Journal Article

Noy, A.; de Vos, S.; Thieblemont, C.; Martin, P.; Flowers, C. R.; Morschhauser, F.; Collins, G. P.; Ma, S.; Coleman, M.; Peles, S.; more...
Blood (2017)

Fulltext@MSK | Save

High frequency of identical clonal immunoglobulin DNA in pre-treatment tumor and plasma from untreated patients with HIV-associated lymphoma: Prospective multicenter trial of the AIDS malignancies consortium (AMC 064)

Journal Article

Wagner-Johnston, N. D.; Lensing, S.; Noy, A.; Ratner, L.; Henry, D.; Lee, J. Y.; Silver, S.; Faham, M.; Ambinder, R. F.
Leukemia and Lymphoma (2017)

Fulltext@MSK | Save

Safety and efficacy of single-agent ibrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL): A multicenter, open-label, phase 2 study

Meeting Abstract

Collins, G. P.; Noy, A.; Vos, S.; Thieblemont, C.; Martin, P.; Flowers, C.; Morschhauser, F.; Ma, S.; Coleman, M.; Peles, S.; more...
Hematological Oncology (2017)

Fulltext@MSK | Save

Defining progression free survival after multiple lines of therapy and impact of dynamic changes in FLIPI for multiply relapsed follicular lymphoma in the rituximab era

Meeting Abstract

Batlevi, C.; Alperovich, A.; Ni, A.; Soumerai, J.; Smith, K.; Ying, Z.; Caron, P.; Drullinsky, P.; Gerecitano, J.; Hamilton, A.; more...
Hematological Oncology (2017)

Fulltext@MSK | Save

Time from prognosis to 2nd treatment is a promising surrogate for overall survival in patients with advanced stage follicular lymphoma

Meeting Abstract

Soumerai, J. D.; Ni, A.; Batlevi, C.; Alperovich, A.; Bantilan, K. S.; Palomba, M.; Gerecitano, J. F.; Noy, A.; Hamlin, P.; Moskowitz, C. H.; more...
Hematological Oncology (2017)

Fulltext@MSK | Save

A Phase I study of ibrutinib combined with rituximab, ifosfamide, carboplatin, and etoposide in patients with relapsed or primary diffuse large B-cell lymphoma

Meeting Abstract

Sauter, C. S.; Matasar, M. J.; Schoder, H.; Drullinsky, P.; Gerecitano, J.; Kumar, A.; Noy, A.; Palomba, M. L.; Portlock, C. S.; Straus, D. J.; more...
Hematological Oncology (2017)

Fulltext@MSK | Save

A pilot study of brentuximab vedotin and AVD chemotherapy followed by 20 Gy involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma

Meeting Abstract

Kumar, A.; Casulo, C.; Advani, R.; Budde, E.; Barr, P. M.; Batlevi, C. L.; Chen, R.; Constine, L. S.; Courtien, A. I.; Dandapani, S. V.; more...
Hematological Oncology (2017)

Fulltext@MSK | Save

Risk-adapted therapy in adults with Burkitt lymphoma: Updated results of a multicenter prospective Phase II study of DA-EPOCH-R

Meeting Abstract

Dunleavy, K.; Roschewski, M.; Abramson, J. S.; Link, B.; Parekh, S.; Jagadeesh, D.; Bierman, P.; Watson, P. R.; Peace, D.; Hanna, W.; more...
Hematological Oncology (2017)

Fulltext@MSK | Save

Baseline metabolic tumor volume is an independent prognostic factor for relapsed and refractory Hodgkin lymphoma patients receiving PET-adapted salvage therapy with brentuximab vedotin and augmented ICE

Meeting Abstract

Moskowitz, A. J.; Schöder, H.; Gavane, S.; Thoren, K. L.; Fleisher, M.; Yahalom, J.; McCall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; more...
Hematological Oncology (2017)

Fulltext@MSK | Save